These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36463197)

  • 1. Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen.
    Lin YH; Lin CH; Huang YY; Chen HY; Tai AS; Fu SC; Hsieh SH; Sun JH; Chen ST; Lin SH
    Eur J Med Res; 2022 Dec; 27(1):273. PubMed ID: 36463197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study).
    Bajaj HS; Venn K; Ye C; Patrick A; Kalra S; Khandwala H; Aslam N; Twum-Barima D; Aronson R
    Diabetes Care; 2017 Feb; 40(2):194-200. PubMed ID: 27913575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
    Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
    J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study.
    Oe Y; Nomoto H; Nakamura A; Kuwabara S; Takahashi Y; Yasui A; Izumihara R; Miya A; Kameda H; Cho KY; Atsumi T; Miyoshi H
    J Diabetes Res; 2022; 2022():5603864. PubMed ID: 35097130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy.
    Liu JS; Su SC; Kuo FC; Li PF; Huang CL; Ho LJ; Chen KC; Liu YC; Lin CP; Cheng AC; Lee CH; Lin FH; Hung YJ; Liu HY; Lu CH; Hsieh CH
    Medicine (Baltimore); 2023 Mar; 102(10):e33167. PubMed ID: 36897731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COMPARISON OF BASAL INSULIN REGIMENS ON GLYCEMIC VARIABILITY IN NONCRITICALLY ILL PATIENTS WITH TYPE 2 DIABETES.
    Haw JS; Farrokhi F; Smiley D; Peng L; Reyes D; Newton C; Pasquel FJ; Vellanki P; Umpierrez GE
    Endocr Pract; 2015 Dec; 21(12):1333-43. PubMed ID: 26307899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.
    Davies ML; Pham DQ; Drab SR
    Pharmacotherapy; 2016 Aug; 36(8):893-905. PubMed ID: 27340935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor agonist use during hospitalisation: Better glycaemic control compared to premixed insulin.
    Jervis M; Mitchell AP; Islam N; Mustafa OG; Kelly PA; Whyte MB
    Diabetes Metab Res Rev; 2022 Nov; 38(8):e3574. PubMed ID: 36052434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk.
    FLAT-SUGAR Trial Investigators
    Diabetes Care; 2016 Jun; 39(6):973-81. PubMed ID: 27208320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes.
    Henao-Carrillo DC; Muñoz OM; Gómez AM; Rondón M; Colón C; Chica L; Rubio C; León-Vargas F; Calvachi MA; Perea AM
    J Clin Transl Endocrinol; 2018 Jun; 12():8-12. PubMed ID: 29892561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report.
    Matsutani D; Sakamoto M; Iuchi H; Minato S; Suzuki H; Kayama Y; Takeda N; Horiuchi R; Utsunomiya K
    Cardiovasc Diabetol; 2018 Mar; 17(1):36. PubMed ID: 29514695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal Insulin Reduces Glucose Variability and Hypoglycaemia Compared to Premixed Insulin in Type 2 Diabetes Patients: A Study Based on Continuous Glucose Monitoring Systems.
    Wang H; Zhou Y; Wang Y; Cai T; Hu Y; Jing T; Ding B; Su X; Li H; Ma J
    Front Endocrinol (Lausanne); 2022; 13():791439. PubMed ID: 35574003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?].
    Nauck M; Wilhelm B
    MMW Fortschr Med; 2017 Jun; 159(Suppl 5):7-15. PubMed ID: 28643293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
    Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
    Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Impact of GLP-1 receptor agonists in veterans receiving basal-bolus insulin.
    Hopton OM; Waterbury NV; Egge JA; Lund BC
    Pharmacotherapy; 2022 Jan; 42(1):45-52. PubMed ID: 34807465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COMPARING CLINICAL OUTCOMES AND COSTS FOR DIFFERENT TREATMENT INTENSIFICATION APPROACHES IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON BASAL INSULIN: ADDING GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS VERSUS ADDING RAPID-ACTING INSULIN OR INCREASING BASAL INSULIN DOSE.
    Levin P; Fan T; Song X; Nero D; Davis B; Chu BC
    Endocr Pract; 2017 Nov; 23(11):1316-1324. PubMed ID: 28816532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of CGM-Derived Measures of Glycemic Variability Between Pancreatogenic Diabetes and Type 2 Diabetes Mellitus.
    Shivaprasad C; Aiswarya Y; Kejal S; Sridevi A; Anupam B; Ramdas B; Gautham K; Aarudhra P
    J Diabetes Sci Technol; 2021 Jan; 15(1):134-140. PubMed ID: 31282179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system.
    Li LQ; Yao MY; Ma JX; Xue P; Li YK
    Endocr J; 2019 Oct; 66(10):871-880. PubMed ID: 31243192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.